BioSpace News Archive

Policy

Biogen Sees Rocky 2022 Finish with Further Aduhelm, Lecanemab Scrutiny

Two documents recently came to light: first, the results of a congressional investigation into the approval of Aduhelm; second, a revised clinical trial consent form for lecanemab.

January 3, 2023
·
3 min read
·
Heather McKenzie
Business

Gilead, EVOQ Unite on ‘Potential Breakthrough’ Treatment for RA, Lupus

Gilead and EVOQ Therapeutics announced a partnership to develop immunotherapies for rheumatoid arthritis and lupus.

January 3, 2023
·
2 min read
·
Rosemary Scott
Drug Development

Chemomab Claims Mid-Stage Win in NASH

Chemomab’s experimental antibody shows promise in NASH.

January 3, 2023
·
2 min read
·
Tristan Manalac
Policy

Aurinia and Sun Pharma File Joint Motion to Settle Patent Dispute

Aurinia and Sun Pharma agree to file a joint motion to dismiss a key patent dispute.

January 3, 2023
·
2 min read
·
George Budwell
New study publication reinforces the clinical benefits of Blue Light Cystoscopy in the ASC setting; supports ongoing initiatives to further improve reimbursement

Photocure ASA, The Bladder Cancer Company, announces the publication of the study ‘Clinical and Economic Impact of Blue Light Cystoscopy in the Management of NMIBC* at U.S. Ambulatory Surgical Centers: What is the Site-of-Service Disparity?’ in Urologic Oncology this week.

January 3, 2023
·
6 min read
Biotech Bay

Mainz Biomed Provides Year-End 2022 Corporate Review

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced a corporate summary for the fiscal year ended December 31, 2022.

January 3, 2023
·
14 min read
Tessa Therapeutics Provides Strategic Outlook and Corporate Update for 2023

Tessa Therapeutics Ltd. announced that the company will prioritize development of its allogeneic “off-the-shelf” CD30.CAR-modified Epstein-Barr virus-specific T-cell therapy platform, while seeking strategic options for the development of its TT11 autologous CAR-T platform with other companies.

January 3, 2023
·
5 min read
Biotech Bay

IDEAYA Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023

IDEAYA Biosciences, Inc., a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the 41st Annual J.P. Morgan Healthcare Conference.

January 3, 2023
·
2 min read
Business

Cardinal Health to Announce Second-Quarter Results for Fiscal Year 2023 on February 2

Cardinal Health (NYSE: CAH) plans to release second-quarter financial results for its fiscal year 2023 on February 2, prior to the opening of trading on the New York Stock Exchange.

January 3, 2023
·
1 min read
Drug Development

NRx Pharmaceuticals Initiates Phase 3 Trial Treating Patients with Bipolar Depression with Acute Suicidality - First Clinical Site Contracted

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced that its first clinical trial site has been contracted and that first dosing of patients is expected in early 2023.

January 3, 2023
·
4 min read